Dr. Anita R. Scribner, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at San Antonio (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 575
Licensed in Texas since 1997, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of Texas Medical School at San Antonio
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license K3455 (first issued 1997; active) -
Infectious Disease Physician
TX license K3455 (first issued 1997; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Good Shepherd Medical Center Longview, TX
- Longview Regional Medical Center Longview, TX
Medical groups
- Associated Clinicians of East Texas (108 clinicians)
- Special Health Resources for Texas, Incorporated (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 575
- Services billed
- 2,555
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 445 | 397 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 325 | 142 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 149 | 47 |
| Blood test, comprehensive group of blood chemicals | 144 | 47 |
| Established patient office or other outpatient visit, 30-39 minutes | 139 | 80 |
| Established patient office or other outpatient visit, 20-29 minutes | 108 | 76 |
| Insertion of needle into vein for collection of blood sample | 99 | 59 |
| Red blood cell sedimentation rate, to detect inflammation, automated | 56 | 20 |
| Measurement c-reactive protein for detection of infection or inflammation | 54 | 19 |
| New patient office or other outpatient visit, 30-44 minutes | 51 | 51 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 289 |
| Dovato (dolutegravir sodium/lamivudine) | 240 |
| Atorvastatin Calcium Other prescribers in Longview, TX | 191 |
| Tivicay (dolutegravir sodium) | 155 |
| Symtuza (darunavir/cob/emtri/tenof alaf) | 153 |
| Amlodipine Besylate Other prescribers in Longview, TX | 153 |
| Doxycycline Hyclate Other prescribers in Longview, TX | 152 |
| Daptomycin | 132 |
| Ozempic (semaglutide) Other prescribers in Longview, TX | 130 |
| Descovy (emtricitabine/tenofov alafenam) | 127 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 18 companies reported 96 payments worth $2,369 in total to this clinician.
| Gilead Sciences, Inc. | $885 |
|---|---|
| Viiv Healthcare Company | $704 |
| Merck Sharp & Dohme LLC | $164 |
| AbbVie Inc. | $124 |
| AstraZeneca Pharmaceuticals LP | $98.49 |
| Paratek Pharmaceuticals, Inc. | $84.81 |
| Novo Nordisk Inc | $58.18 |
| Hologic Sales and Service, LLC | $40.91 |
| Food and Beverage | $2,369 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $150,248 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Bict…
Merck Sharp & Dohme LLC - A Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir ISL and Ulonivirine ULO Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Te…
Merck Sharp & Dohme LLC - A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
AbbVie Inc. · Terminated · NCT06032546 - A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in HIV-1 Infected Trea…
Merck Sharp & Dohme LLC - M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of…
AbbVie Inc. - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalim…
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.